Shopping Cart
- Remove All
- Your shopping cart is currently empty
TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,720 | 10-14 weeks | |
50 mg | $3,580 | 10-14 weeks | |
100 mg | $4,900 | 10-14 weeks |
Description | TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2. |
Targets&IC50 | NEP:9.2(pIC50), AT1:(pKi)8.9 |
In vitro | TD-0212 exhibits improved dual AT1/NEP inhibition activity and may present a reduced angioedema risk compared to dual ACE/NEP inhibition. |
In vivo | In renin-dependent and non-dependent hypertension models, TD-0212 can lower blood pressure, similar to omapatrilat and the combination of AT1 receptor antagonist and NEP inhibitor. |
Molecular Weight | 641.67 |
Formula | C30H35F4N3O6S |
Cas No. | 1073549-11-7 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (194.80 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.